Amsterdam, The Netherlands, May 25, 2020 – Kiadis Pharma N.V. (“Kiadis Pharma” or the “Company”) (Euronext Amsterdam and Brussels: KDS), a clinical stage biopharmaceutical company, today announces an abstract highlighting data related to the Company’s natural killer (NK) cell therapy program has been accepted for presentation at the virtual edition of the International Society of Cell & Gene Therapy (ISCT) annual meeting taking place May 28 – 29, 2020.
The ISCT abstract is now available at http://www.isct2020.com/. The details of the poster presentation are as follows:
·Poster #228: This poster presents data on a method for high expansion of NK cells with “memory-like” phenotype. This method combines pre-activation of NK cells with cytokines (IL-12, IL-15, IL-18) and expansion with Kiadis’ PM21-particle platform.
Abstract Details
Title: Cytokine pre-activation enhances PM21-particle driven NK cell expansion.
Presenter: Alicja J. Copik
Affiliation: University of Central Florida
Session title: Virtual poster session
Kiadis Pharma Contacts
| Kiadis Pharma: Maryann Cimino, Sr. Manager, Corporate Affairs Tel. +1 617 710 7305 m.cimino@kiadis.com | Optimum Strategic Communications: Mary Clark, Supriya Mathur, Hollie Vile Tel: +44 203 950 9144 David Brilleslijper (Amsterdam) Tel: +31 610 942 514 kiadis@optimumcomms.com |
Dutch Translation/Nederlandse vertaling
Kiadis Pharma kondigt presentatie aan op ISCT 2020 congres
Amsterdam, Nederland, 25 mei 2020 – Kiadis Pharma nv (‘Kiadis’) (Euronext Amsterdam en Brussel: KDS), een biofarmaceutische onderneming gericht op onderzoek in de klinische fase, kondigt vandaag aan dat een presentatie over het Kiadis NK-celtherapieprogramma is geaccepteerd voor ISCT congres (International Society of Cell & Gene Therapy), welke plaatsvindt op 28 en 29 mei 2020.
De ISCT-presentatie is nu beschikbaar op http://www.isct2020.com/. Hier volgen nadere gegevens van de presentatie:
·Presentatie nr. 228: De posterpresentatie toont gegevens over een methode voor de hoge expansie van NK-cellen (Natural Killer) met een uniek fenotype. Deze methode combineert preactivering van NK-cellen met cytokinen (IL-12, IL-15, IL-18) en expansie met het PM21-deeltjesproductieplatform van Kiadis.
Details van de presentatie
Titel: Cytokine-preactivering zorgt voor verdere verbetering van op PM21 gebaseerde NK-celexpansie.
Presentator: Alicja J. Copik
Lid van: University of Central Florida
Sessietitel: Virtuele posterpresentatie
Dit persbericht vormt een vertaling van het gepubliceerde Engelstalige persbericht. Bij eventuele verschillen is de tekst van het Engelstalige persbericht altijd bepalend.
About Kiadis Pharma’s K-NK-Cell Therapies
Kiadis Pharma’s NK-cell programs consist of off-the-shelf and haplo donor cell therapy products for the treatment of liquid and solid tumors as adjunctive and stand-alone therapies.
The Company’s NK-cell PM21 particle technology enables improved ex vivo expansion and activation of anti-cancer cytotoxic NK-cells supporting multiple high-dose infusions. Kiadis Pharma’s proprietary off-the-shelf NK-cell platform is based on NK-cells from unique universal donors. The Kiadis Pharma off-the-shelf K-NK platform can make NK-cell therapy product rapidly and economically available for a broad patient population across a potentially wide range of indications.
Kiadis Pharma is clinically developing K-NK003 for the treatment of relapse/refractory acute myeloid leukemia. The Company is also developing K-NK002, which is administered as an adjunctive immunotherapeutic on top of HSCT and provides functional, mature and potent NK-cells from a haploidentical family member. In addition, the Company has pre-clinical programs evaluating NK-cell therapy for the treatment of solid tumors.
About Kiadis Pharma
Founded in 1997, Kiadis Pharma is building a fully integrated biopharmaceutical company committed to developing innovative therapies for patients with life-threatening diseases. With headquarters in Amsterdam, the Netherlands, and offices and activities across the United States, Kiadis Pharma is reimagining medicine by leveraging the natural strengths of humanity and our collective immune system to source the best cells for life.
Kiadis Pharma is listed on the regulated market of Euronext Amsterdam and Euronext Brussels since July 2, 2015, under the symbol KDS. Learn more at www.kiadis.com.
Forward Looking Statements
Certain statements, beliefs and opinions in this press release are forward-looking, which reflect Kiadis Pharma’s or, as appropriate, Kiadis Pharma’s officers’ current expectations and projections about future events. By their nature, forward-looking statements involve a number of known and unknown risks, uncertainties and assumptions that could cause actual results, performance, achievements or events to differ materially from those expressed, anticipated or implied by the forward-looking statements. These risks, uncertainties and assumptions could adversely affect the outcome and financial effects of the plans and events described herein. A multitude of factors including, but not limited to, changes in demand, regulation, competition and technology, can cause actual events, performance, achievements or results to differ significantly from any anticipated or implied development. Forward-looking statements contained in this press release regarding past trends or activities should not be taken as a representation that such trends or activities will continue in the future. As a result, Kiadis Pharma expressly disclaims any obligation or undertaking to release any update or revisions to any forward-looking statements in this press release as a result of any change in expectations or projections, or any change in events, conditions, assumptions or circumstances on which these forward-looking statements are based. Neither Kiadis Pharma nor its advisers or representatives nor any of its subsidiary undertakings or any such person’s officers or employees guarantees that the assumptions underlying such forward-looking statements are free from errors nor does either accept any responsibility for the future accuracy of the forward-looking statements contained in this press release or the actual occurrence of the anticipated or implied developments. You should not place undue reliance on forward-looking statements, which speak only as of the date of this press release.